Zevra Therapeutics Begins Trading As ZVRA; Formerly KemPharm, Inc.

Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ZVRA" starting today, March 1, 2023
 

New Company name, Zevra, is Greek for zebra, the internationally recognized symbol for the rare disease community

CELEBRATION, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NASDAQ:ZVRA) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol "ZVRA" on the Nasdaq Global Select Market at market open today, March 1, 2023.

The Company's new corporate name, along with the corresponding ticker symbol, embody Zevra's unwavering commitment to the rare disease community as it pursues its primary mission to deliver life-changing treatments to people with rare conditions, their families and caregivers who desperately need better options.

Zevra is currently developing arimoclomol, an orally-delivered, first-in-class investigational product candidate for the treatment of Niemann-Pick type C disease ("NPC"). NPC, a rare disease with no currently approved treatments in the U.S., primarily affects children and is often fatal, causing progressive loss of brain, nerve, liver, spleen, bone marrow, and lung functions. The U.S. Food and Drug Administration ("FDA") has granted arimoclomol orphan drug designation, Fast Track designation, and rare pediatric disease designation for the treatment of NPC.

In addition, Zevra is also advancing KP1077, a product candidate based on Zevra's prodrug of d-methylphenidate, serdexmethylphenidate ("SDX"), which is currently being evaluated in a Phase 2 trial for the treatment of idiopathic hypersomnia ("IH"), a rare sleep disorder. Pending the results from that trial, the Company plans to conduct a pivotal Phase 3 study in IH, with the potential to study an expanded indication in narcolepsy.

Zevra expects several key milestones in 2023, including the planned resubmission of the New Drug Application ("NDA") for arimoclomol to the FDA as early as Q3 2023, an interim and final data readout for KP1077 in IH, and the potential achievement of one or more certain commercial sales milestones for our partnered asset, AZSTARYS®, during FY 2023.

Visit Zevra's new corporate website at zevra.com to learn more.